Shugeng Cao, Ph.D.
Shugeng Cao carried out his doctoral research at the National University of Singapore (NUS), where Shugeng studied the tropical plants collected from eastern Malaysia at Borneo, which is shared with Indonesia and Brunei. Assay-guided separation led to the isolation of many new cytotoxic compounds. After his graduate study, Shugeng joined MerLion Pharmaceuticals Pte Ltd. Shugeng's research at the company involved the study of biologically active compounds from bacteria, fungi, plant, and marine organisms.
He resigned from his position at MerLion Pharma and joined the Kingston Group at Virginia Tech (VT) in April 2003. At Virginia Tech, Shugeng carried out assay-guided separation of anticancer, anti-malarial, and CNS active compounds from marine, and plants from tropical countries (Suriname and Madagascar).
Shugeng moved to Boston as the Director of the Marcus Natural Product Lab under Dr. Jon Clardy at Harvard Medical School (HMS) in December 2008.
In 2013, Shugeng moved to University of Hawaii Cancer Center (UHCC) as an independent researcher.
In 2015 he relocated to Daniel K. Inouye College of Pharmacy (DKICP), UH Hilo.